Loading…

Increased gene expression of TIMP1 and CHI3L1 in fine‐needle aspiration biopsy samples from papillary thyroid cancer as compared to benign nodules

Background Thyroid nodules are common ultrasound findings with malignancy rate 7%–15%. Our objective was to assess the relative expression of the tissue inhibitor of metalloproteinase‐1 gene (TIMP1) and chitinase‐3‐like protein 1 gene (CHI3L1) in fine‐needle aspiration biopsy (FNAB) washouts and the...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostic cytopathology 2021-09, Vol.49 (9), p.1045-1051
Main Authors: Dimitrova, Inna, Shinkov, Alexander, Dodova, Rumyana, Ivanova, Radina, Kirilov, Georgi, Kyurkchiyan, Silva, Kaneva, Radka, Kovatcheva, Roussanka
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Thyroid nodules are common ultrasound findings with malignancy rate 7%–15%. Our objective was to assess the relative expression of the tissue inhibitor of metalloproteinase‐1 gene (TIMP1) and chitinase‐3‐like protein 1 gene (CHI3L1) in fine‐needle aspiration biopsy (FNAB) washouts and the serum levels of their protein products (TIMP‐1 and chitinase‐3‐like protein 1 known as YKL‐40) in patients with papillary thyroid cancer (PTC) and patients with benign nodules. Furthermore, the correlation between gene expression and circulating protein product was evaluated. Methods Eighty patients who underwent FNAB in one tertiary center were recruited in the study. Forty with Bethesda V and VI nodules were operated and PTC was confirmed. The other 40 patients were with Bethesda II nodules. TIMP‐1 and YKL‐40 serum levels were measured in all subjects. The TIMP1 and CHI3L1 expression was assessed in FNAB washouts from 20 PTC patients and 20 benign cases using quantitative PCR. Results The relative expression of TIMP1 and CHI3L1 was significantly higher in the PTC group than in the benign group (p 
ISSN:8755-1039
1097-0339
DOI:10.1002/dc.24816